

Rev04
Update: Aug,21,2025

DATASHEET

Anti-Abatacept Antibody (CT.F3), mAb, Mouse

Cat. No.: A02262

Overview

Specificity	This product is specific for Abatacept.
Host Species	Mouse
Immunogen	Abatacept
Conjugate	Unconjugated

Applications

Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.


Application	Recommended Usage
Sandwich ELISA	0.5-2 µg/ml
ELISA	0.01-1 µg/ml

Properties

Form	Lyophilized
Storage Buffer	Lyophilized with PBS, pH 7.2, containing 0.02% sodium azide.
Reconstitution	Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.
Storage Instructions	The lyophilized product remains stable for 1 year at -20°C from the date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8°C or for 12 months at -20°C or below. Avoid repeated freezing and thawing cycles.
Purification	Protein A affinity column
Isotype	Mouse IgG1, κ
Clonality	Monoclonal

Clone ID	CT.F3
Note	GenScript can customize this product per customer's request including product size, buffer components, etc.


Examples



BLI (Biolayer interferometry) binding affinity measurements of Anti-Abatacept Antibody (CT.F3), mAb, Mouse (GenScript, A02262) to Abatacept.

Anti-Abatacept Antibody (CT.F3), mAb, Mouse (GenScript, A02262) captured on MFC (Anti-Mouse IgG Fc) Probes can bind Abatacept with a dissociation constant (KD) of 1.71E-09M.

MRD analysis of the detection of Abatacept in biological matrix by A02262 (CT.F3) and A02263 (CT.E8)




MRD analysis of the detection of Abatacept in biological matrix by A02262 (CT.F3) and A02263 (CT.E8).

The MRD is the minimum dilution necessary for the detection of Abatacept in biological matrix with least interference. Serum samples from cynomolgus monkey were serially diluted to determine the MRD of this assay, and the test result suggested that MRD was as 1:10.

In the ELISA assay shown in this chart, Anti-Abatacept Antibody (CT.F3), mAb, Mouse (GenScript, A02262) was coated at a concentration of 1 µg/ml, and Anti-Abatacept Antibody (CT.E8), mAb, Mouse (GenScript, A02263) conjugated with Biotin was used as a detection antibody at a concentration of 0.8 µg/ml.

In this MRD analysis, the same conclusion was reached when Anti-Abatacept Antibody (CT.E8), mAb, Mouse (GenScript, A02263) was used as a coated antibody at a concentration of 1 µg/ml and Anti-Abatacept Antibody (CT.F3), mAb, Mouse (GenScript, A02262) conjugated with Biotin was used as a detection antibody at a concentration of 0.8 µg/ml (data not shown).

MRD analysis of the detection of Abatacept in biological matrix by A02262 (CT.F3) and anti-human IgG Fc antibody




MRD analysis of the detection of Abatacept in biological matrix by A02262 (CT.F3) and anti-human IgG Fc antibody.

The MRD is the minimum dilution necessary for the detection of Abatacept in biological matrix with least interference. Serum samples from cynomolgus monkey were serially diluted to determine the MRD of this assay, and the test result suggested that MRD was as 1:10.

In the ELISA assay shown in this chart, Anti-Abatacept Antibody (CT.F3), mAb, Mouse (GenScript, A02262) was coated at a concentration of 1 µg/ml, and Mouse Anti-Human IgG Fc Antibody (50B4A9)[HRP], mAb (GenScript, A01854) was used as a detection antibody at a dilution of 1:2000.

Standard curve and specificity analysis of the detection of Abatacept by A02262 (CT.F3) and A02263 (CT.E8)




Standard curve and specificity analysis of the detection of Abatacept by A02262 (CT.F3) and A02263 (CT.E8).

Abatacept standard samples at 8 concentrations were spiked with 10 µg/mL of human IgG. The test result demonstrated that the high concentration of human IgG did not interfere with the detection of Abatacept.

In the ELISA assay shown in this chart, Anti-Abatacept Antibody (CT.F3), mAb, Mouse (GenScript, A02262) was coated at a concentration of 1 µg/ml, and Anti-Abatacept Antibody (CT.E8), mAb, Mouse (GenScript, A02263) conjugated with Biotin was used as a detection antibody at a concentration of 0.8 µg/ml. The same conclusion was reached when Anti-Abatacept Antibody (CT.E8), mAb, Mouse (GenScript, A02263) was used as a coated antibody at a concentration of 1 µg/ml and Anti-Abatacept Antibody (CT.F3), mAb, Mouse (GenScript, A02262) conjugated with Biotin was used as a detection antibody at a concentration of 0.8 µg/ml (data not shown). In this assay, a four-parameter logistic curve fitting program was used to create a standard curve with the R-Square is greater than 0.99. The typical dynamic range of the assay is 156-10,000 ng/ml and its sensitivity of detecting Abatacept is up to 156 ng/ml.

Standard curve and specificity analysis of the detection of Abatacept by A02262 (CT.F3) and anti-human IgG Fc antibody



Standard curve and specificity analysis of the detection of Abatacept by A02262 (CT.F3) and anti-human IgG Fc antibody.

Abatacept standard samples at 8 concentrations were spiked with 2 µg/mL of human IgG. The test result demonstrated that the high concentration of human IgG did not interfere with the detection of Abatacept.

In the ELISA assay shown in this chart, Anti-Abatacept Antibody (CT.F3), mAb, Mouse (GenScript, A02262) was coated at a concentration of 1 µg/ml, and Mouse Anti-Human IgG Fc Antibody (50B4A9)[HRP], mAb (GenScript, A01854) was used as a detection antibody at a dilution of 1:2000.

In this assay, a four-parameter logistic curve fitting program was used to create a standard curve with the R-Square is greater than 0.99. The typical dynamic range of the assay is 31.25-2,000 ng/ml and its sensitivity of detecting Abatacept is up to 31.25 ng/ml.

Background

Target Background : Abatacept, also known as Orencia, is a medication utilized for the treatment of autoimmune diseases like rheumatoid arthritis. By interfering with the immune activity of T cells, Abatacept helps in managing these conditions. It is a fusion protein that combines the extracellular domain of CTLA-4 with the Fc region of the immunoglobulin IgG1. Abatacept is a medication that is utilized as a second-line treatment for adults with moderate to severe rheumatoid arthritis (RA). For individuals whose RA is severe and rapidly progressing, it can be used as a first-line treatment. Furthermore, Abatacept is also prescribed for the treatment of psoriatic arthritis and juvenile idiopathic arthritis.

Synonyms : Abatacept, Orencia, Anti-CTLA-4 antibody, CTLA4Ig, BMS-188667, CTL A4-Ig B7 Inhibitor, RG2077

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.

Manufacturer: Nanjing GenScript Biotech Co., Ltd. No. 28Yongxi Road, Jiangning District, Nanjing, Jiangsu, China